This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Prognosis of vulval cancer

Authoring team

Prognosis depends upon:

  • stage - 90% 5 year survival for stage I disease to 15% survival for stage IV

  • lymph node status - 50% 5 year survival for patients with lymphatic metastases to 90% for those without; those with more than three positive nodes do badly irrespective of stage

More than half (53%) of women diagnosed with vaginal or vulval cancer in England survive their disease for ten years or more (2009-13).

Almost two-thirds (64%) of women diagnosed with vaginal or vulval cancer in England survive their disease for five years or more (2009-2013).

More than 8 in 10 (82%) women diagnosed with vaginal or vulval cancer in England survive their disease for one year or more (2009-2013).

Vagina and vulva cancer survival in England is highest for women diagnosed aged under 50 years old (2009-2013).

More than 8 in 10 women in England diagnosed with vagina or vulva cancer aged 15-49 survive their disease for five years or more, compared with almost 6 in 10 women diagnosed aged 70-89 (2009-2013)

 

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.